This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
CAR T-Cells
Pre-conditioning chemotherapy
Pre-conditioning therapy
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Medical College of Wisconsin
Madison, Wisconsin, United States
Number of Participants With Treatment-Related Adverse Events
Determine the safety of Descartes-11 in patients with relapsed/refractory multiple myeloma
Time frame: Time Frame: 21 days
Disease Assessment Based on International Myeloma Working Group (IMWG) Criteria
Patience with Complete response (CR) according to the International Myeloma Working Group (IMWG).
Time frame: Disease assessment is on Day 21 (or at least 14 days after first Descartes-11 infusion)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.